Skip to content

A randomized, double-blind, controlled trial for FESS combined with oral steroids in the treatment of eosinophilic chronic rhinosinusitis with nasal polyposis

A randomized, double-blind, controlled trial for FESS combined with oral steroids in the treatment of eosinophilic chronic rhinosinusitis with nasal polyposis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019974
Enrollment
Unknown
Registered
2018-12-10
Start date
2018-12-05
Completion date
Unknown
Last updated
2019-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eosinophilic chronic rhinosinusitis with nasal polyposis

Interventions

Group 1:Oral glucocorticoid

Sponsors

The Third Affiliated Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients aged from 18 to 60 year old with the percentage of eosinophil of inflammatory cells in polyps sections above 10% are included. Either women or men are enrolled. All the patients underwent non-sinonasal-related surgeries.

Exclusion criteria

Exclusion criteria: Patients using of corticosteroids or antihistamine drug within the 2 weeks or with acute infection one month prior to surgery or will be excluded. Subjects who had allergic fungal rhinosinusitis, autoimmune diseases, severe heart, liver and kidney insufficiency and the systematic glucocorticoid contraindication (hypertension, diabetes, cataract, glaucoma, active hepatitis, digestive ulcer, severe osteoporosis and so on) were excluded. Pregnant and lactating women were not included.

Design outcomes

Primary

MeasureTime frame
Lund-Kennedy Score;

Secondary

MeasureTime frame
VAS score;SNOT22 score;

Countries

China

Contacts

Public ContactGehua Zhang

The Third Affiliated Hospital, Sun Yat-sen University

gehuazh@hotmail.com+86 18922102653

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026